Explore

Parents Utilize AI Chatbot to Aid in Diagnosing Daughter's Rare Medical Conditions

Parents Utilize AI Chatbot to Aid in Diagnosing Daughter's Rare Medical Conditions

Hilary and Matt Eaton, both scientists in the biotech industry, used ChatGPT to help understand their daughter Olivia's complex and confounding medical symptoms. For most of her 5-year-old life, Olivia experienced frequent illnesses, developmental delays, and slow wound healing. After receiving alarming lab results showing low antibody levels, Hilary Eaton input Olivia's symptoms and test results into ChatGPT. The chatbot suggested common variable immunodeficiency (CVID) as a possible diagnosis, which, while not the ultimate cause, provided a starting point for further medical discussions. The Eatons also used AI to analyze their family's genome sequencing data, identifying potential genetic mutations. This AI-assisted research helped them uncover that Olivia had Okur-Chung neurodevelopmental syndrome, a rare genetic disorder affecting approximately 1 in 100,000 people, which explained her low antibody production and other symptoms. Their use of AI also led them to suggest an EEG for Olivia's motor tics, w...

UNC-Chapel Hill and Emory University Lead Initiative to Build World's Largest Rare Disease Data Resource

UNC-Chapel Hill and Emory University Lead Initiative to Build World's Largest Rare Disease Data Resource

UNC-Chapel Hill and Emory University are spearheading a groundbreaking research initiative to establish the world's largest comprehensive data resource for diagnosing rare diseases. This project, supported by an award of up to $35 million from the Advanced Research Projects Agency for Health (a U.S. Department of Health and Human Services agency), aims to leverage artificial intelligence (AI) to drive insights, facilitate earlier diagnoses, improve medical care, and accelerate treatment discovery. The initiative will acquire data from various sources, including patient registries, real-world clinical data, health records, insurance claims, medical imaging, video technologies, and patient surveys. The goal is to create a large-scale dataset spanning approximately 2,700 rare diseases to train AI models. These models will then be deployed in diagnostic settings to help clinicians interpret findings more effectively and provide answers to patients sooner. Melissa Haendel, lead scientist on the project, emphasi...

AI Chatbots Show Varied Performance in Breast Cancer Information, Study Finds

AI Chatbots Show Varied Performance in Breast Cancer Information, Study Finds

A recent study published in *Scientific Reports* conducted a head-to-head comparison of five leading large language models (LLMs)—ChatGPT-5.2, ChatGPT-4o, Gemini 3.0, DeepSeek, and ERNIE Bot—to evaluate their effectiveness in providing breast cancer health information. The research assessed the chatbots using 90 multiple-choice questions, 10 de-identified clinical cases, and responses to 20 common patient concerns. While all five models demonstrated high accuracy on standardized breast cancer knowledge questions, ranging from 82.22% to 94.44%, their performance varied significantly in linguistic complexity and expert-rated quality measures. Human experts rated ChatGPT-5.2 and DeepSeek highest for completeness, while Gemini 3.0 received the highest readability score. DeepSeek also produced the lowest reading-difficulty score in the automated Chinese-language assessment. The study concluded that no single model excelled across all measures, suggesting the need for multi-faceted evaluation of LLMs in healthca...

Helix Launches Whole Exome+® Sequencing to Accelerate Rare Disease Diagnosis

Helix Launches Whole Exome+® Sequencing to Accelerate Rare Disease Diagnosis

Helix, a leading enterprise genomics platform, has announced the nationwide availability of its Whole Exome+® Sequencing (WES+) diagnostic test. This new offering aims to provide a more comprehensive genetic evaluation for patients with rare and unexplained genetic conditions, integrating broad exome coverage, mitochondrial genome analysis, and genome-wide digital karyotype into a single order. The WES+ test is designed to reduce the time to diagnosis for patients who have often undergone years of inconclusive testing. According to Dr. Cassie Hajek, Medical Director at Helix, WES+ offers clinicians a comprehensive genomic picture from the initial visit, providing broad visibility into potential genomic factors. The launch aligns with evolving clinical guidelines from organizations like the American College of Medical Genetics and the American Academy of Pediatrics, which increasingly recommend exome or genome sequencing as a priority diagnostic approach for conditions such as unexplained developmental dela...

Trusted Health and Mayo Clinic Collaborate to Integrate AI-Driven Workforce Forecasting for Health Systems

Trusted Health and Mayo Clinic Collaborate to Integrate AI-Driven Workforce Forecasting for Health Systems

Trusted Health and Mayo Clinic Collaborate to Integrate AI-Driven Workforce Forecasting for Health Systems

GeneDx and Beren Therapeutics Launch Program to Enhance Niemann-Pick Disease Type C Diagnosis

GeneDx and Beren Therapeutics Launch Program to Enhance Niemann-Pick Disease Type C Diagnosis

GeneDx, a leader in rare disease diagnosis, has partnered with Beren Therapeutics P.B.C. to introduce the NPC GenomeComplete Sponsored Testing Program. This initiative aims to provide no-cost comprehensive genome sequencing for eligible pediatric patients suspected of having Niemann-Pick Disease Type C (NPC). The program targets children exhibiting clinical signs, a family history, or biomarker evidence suggestive of NPC, with the goal of overcoming diagnostic barriers. Niemann-Pick Disease Type C is a rare, progressive, genetic neurodegenerative disorder that leads to neurological decline and premature death. Its varied clinical presentation and age of onset make diagnosis challenging, resulting in approximately two-thirds of U.S. patients remaining undiagnosed. The program offers rapid sequencing for urgent cases, potentially providing preliminary results within 48 hours. This collaboration leverages GeneDx's diagnostic expertise and genomic data with Beren's understanding of NPC to accelerate accurate d...

Atman Health Secures ARPA-H Award to Develop Agentic AI System for Cardiovascular Care

Atman Health Secures ARPA-H Award to Develop Agentic AI System for Cardiovascular Care

Atman Health has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to develop an agentic artificial intelligence system for cardiovascular care, with an initial focus on heart failure. This award is part of ARPA-H's ADVOCATE program, a 39-month initiative aimed at modernizing the management of chronic cardiovascular disease in the United States. The company's AI system is designed to provide continuous patient contact and optimize medication regimens for heart failure patients, addressing the significant gap in specialist access, as nearly half of American counties lack a practicing cardiologist. Atman Health's system separates large language model (LLM) functions for record interpretation and patient communication from clinical decision-making, which is handled by a deterministic engine built on over 9,000 explicit clinical criteria. This approach ensures transparency and auditability of clinical decisions, a critical factor for regulatory approval and physician trust.

Pfizer Seeks Senior Director for AI-Driven Medical Affairs Solutions

Pfizer Seeks Senior Director for AI-Driven Medical Affairs Solutions

Pfizer Seeks Senior Director for AI-Driven Medical Affairs Solutions

Tempus AI Secures $9.5 Million ARPA-H Funding to Develop Autonomous AI for Cardiology

Tempus AI Secures $9.5 Million ARPA-H Funding to Develop Autonomous AI for Cardiology

Tempus AI, Inc. has been awarded up to $9.5 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services. This funding, provided through ARPA-H’s ADVOCATE (Agentic AI-EnableD CardioVascular CAre TransfOrmation) program, is designated for the development of the first autonomous clinical AI agent capable of delivering safe and effective care to patients suffering from heart failure. The initiative aims to create an AI agent that functions as an extension of the clinician team, providing continuous surveillance across clinical data (electronic health records) and consumer-generated data (home-based heart rate monitors). This platform will feature a patient-facing autonomous agent to manage symptoms, medications, virtual rehabilitation, and scheduling, while also integrating with electronic health records for accurate documentation and coordination. The development will include clinical validation of the AI system through a...

Brookings Institution Symposium Explores AI's Impact on Youngest Babies and Neonatal Care

Brookings Institution Symposium Explores AI's Impact on Youngest Babies and Neonatal Care

The Brookings Institution recently hosted a 'Generation AI Starts Early Symposium,' which prompted discussions about the implications of artificial intelligence for the youngest babies, particularly those in neonatal intensive care units (NICUs). Ashley Darcy Mahoney, PhD, NNP, reflected on the symposium, emphasizing the need to consider how AI products can meaningfully support infants and families in the NICU while also protecting the human connection in care. The conversation highlighted the concept of 'Human Reserved' jobs, as described by Bill Gates, suggesting that certain aspects of care must remain fundamentally human even as technology advances. The symposium aimed to bring together parents, nurses, scientists, and technologists to collaboratively determine where AI can enhance care and where human interaction is irreplaceable.

NCCN and Flatiron Health Renew Collaboration to Advance Real-World Data Research in Cancer Care

NCCN and Flatiron Health Renew Collaboration to Advance Real-World Data Research in Cancer Care

The National Comprehensive Cancer Network (NCCN) and Flatiron Health have announced the renewal of their collaboration, extending their partnership through 2028. This agreement, which originated in 2014, aims to advance real-world data (RWD) research across leading cancer centers. As part of the renewed collaboration, Flatiron Health is expanding access for NCCN Member Institutions to its AI-powered oncology intelligence platform, Flatiron Telescope. This platform enables a broader range of users to conduct research and generate insights from Flatiron's curated, de-identified oncology datasets, which span over 6 million patient journeys. The collaboration will continue to provide analytic support, educational programming, and research grants through the Flatiron Grants program, offering up to seven grants biannually to eligible subscribers.

Nanorobotics Market Projected to Reach $31.44 Billion by 2034 Amidst Growth in Precision Medicine

Nanorobotics Market Projected to Reach $31.44 Billion by 2034 Amidst Growth in Precision Medicine

The global nanorobotics market is projected to reach USD 31.44 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 14.9% during the forecast period of 2026-2034, according to a new report by Polaris Market Research. The market, valued at USD 9.01 billion in 2025, is experiencing steady growth driven by the increasing adoption of precision medicine, rising investment in nanomedicine research, and continuous advancements in nano-engineering. Key applications include targeted drug delivery systems, regenerative medicine platforms, and minimally invasive treatment technologies. North America held the largest revenue share in 2025, accounting for approximately 40.9%, primarily due to strong funding for nanomedicine research and advanced healthcare infrastructure. Microbivore nanorobots led the type segment in 2025, while cell-repair nanorobots are expected to see the fastest expansion. Drug delivery remains the largest application segment, with regenerative medicine applications forecasted for r...